{"DataElement":{"publicId":"3437201","version":"1","preferredName":"Ovarian Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for ovarian carcinoma.","longName":"3437168v1.0:3436896v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3437168","version":"1","preferredName":"Ovarian Cancer Stage Grouping","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3304105v1.0:2230143v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3304105","version":"1","preferredName":"Ovarian Carcinoma","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002","longName":"C4908","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1C9C115-8BEA-6AED-E040-BB89AD43131A","latestVersionIndicator":"Yes","beginDate":"2011-11-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-15","modifiedBy":"ONEDATA","dateModified":"2011-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD926170-78B5-C98B-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2012-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3436896","version":"1","preferredName":"Ovarian Cancer and Primary Peritoneal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system.  Ovarian cancer and primary peritoneal carcinoma are surgically/pathologically staged malignancies. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3436896v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"II","valueDescription":"Stage II Ovarian Cancer","ValueMeaning":{"publicId":"2673613","version":"1","preferredName":"Stage II Ovarian Cancer","longName":"2673613","preferredDefinition":"Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Ovarian Cancer AJCC v6 and v7","conceptCode":"C7830","definition":"Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FBFD-9C32-6D15-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-785B-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Ovarian Cancer","ValueMeaning":{"publicId":"2673614","version":"1","preferredName":"Stage IIA Ovarian Cancer","longName":"2673614","preferredDefinition":"Stage IIA includes: T2a, N0, M0. T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Ovarian Cancer AJCC V6 and v7","conceptCode":"C5223","definition":"Stage IIA includes: T2a, N0, M0.  T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC09-7F33-6D1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-7865-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Ovarian Cancer","ValueMeaning":{"publicId":"2673615","version":"1","preferredName":"Stage IIB Ovarian Cancer","longName":"2673615","preferredDefinition":"Stage IIB includes: T2b N0, M0. T2b: Extension and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Ovarian Cancer AJCC v6 and v7","conceptCode":"C5224","definition":"Stage IIB includes: T2b N0, M0.  T2b: Extension and/or implants on other pelvic tissues.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC14-26DF-6D25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-786F-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIC","valueDescription":"Stage IIC Ovarian Cancer","ValueMeaning":{"publicId":"2673616","version":"1","preferredName":"Stage IIC Ovarian Cancer","longName":"2673616","preferredDefinition":"Stage IIC includes: T2c, N0, M0. T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIC Ovarian Cancer AJCC v6 and v7","conceptCode":"C5225","definition":"Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC1F-10D5-6D2D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-7879-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Ovarian Cancer","ValueMeaning":{"publicId":"2673617","version":"1","preferredName":"Stage III Ovarian Cancer","longName":"2673617","preferredDefinition":"Stage III includes: T3, N0, M0. T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Ovarian Cancer AJCC v6 and v7","conceptCode":"C7831","definition":"Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC2A-61D2-6D38-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-7883-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Ovarian Cancer","ValueMeaning":{"publicId":"2673618","version":"1","preferredName":"Stage IIIA Ovarian Cancer","longName":"2673618","preferredDefinition":"Stage IIIA includes: T3a, N0, M0. T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Ovarian Cancer AJCC v6 and v7","conceptCode":"C6258","definition":"Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC35-AD19-6D40-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-788D-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Ovarian Cancer","ValueMeaning":{"publicId":"2673619","version":"1","preferredName":"Stage IIIB Ovarian Cancer","longName":"2673619","preferredDefinition":"Stage IIIB includes: T3b, N0, M0. T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Ovarian Cancer AJCC v6 and v7","conceptCode":"C6259","definition":"Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC41-1A03-6D49-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-7897-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Ovarian Cancer","ValueMeaning":{"publicId":"2673620","version":"1","preferredName":"Stage IIIC Ovarian Cancer","longName":"2673620","preferredDefinition":"Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Ovarian Cancer AJCC v6 and v7","conceptCode":"C6260","definition":"Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC4C-40CE-6D51-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-78A1-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IV","valueDescription":"Stage IV Ovarian Cancer","ValueMeaning":{"publicId":"2673621","version":"1","preferredName":"Stage IV Ovarian Cancer","longName":"2673621","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Ovarian Cancer AJCC v6 and v7","conceptCode":"C7832","definition":"Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FC57-1FFE-6D59-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD926170-78AB-C98B-E040-BB89AD431178","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"ONEDATA","dateModified":"2012-04-13","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Ovarian Cancer","ValueMeaning":{"publicId":"2673611","version":"1","preferredName":"Stage IB Ovarian Cancer","longName":"2673611","preferredDefinition":"Stage IB includes: T1b, N0, M0. T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Ovarian Cancer AJCC v6 and v7","conceptCode":"C5221","definition":"Stage IB includes: T1b, N0, M0. T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820FBE6-CEEB-6D02-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD822090-80E3-307C-E040-BB89AD433070","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"ONEDATA","dateModified":"2012-04-12","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Ovarian Cancer","ValueMeaning":{"publicId":"3436897","version":"1","preferredName":"Stage I Ovarian Cancer","longName":"3436897","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Ovarian Cancer AJCC v6 and v7","conceptCode":"C7829","definition":"Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-80EE-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD822090-8107-307C-E040-BB89AD433070","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"ONEDATA","dateModified":"2012-04-12","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Ovarian Cancer","ValueMeaning":{"publicId":"3436898","version":"1","preferredName":"Stage IA Ovarian Cancer","longName":"3436898","preferredDefinition":"Stage IA includes: T1a, N0, M0. T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Ovarian Cancer AJCC v6 and v7","conceptCode":"C5220","definition":"Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-8111-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD822090-812A-307C-E040-BB89AD433070","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"ONEDATA","dateModified":"2012-04-12","deletedIndicator":"No"},{"value":"IC","valueDescription":"Stage IC Ovarian Cancer","ValueMeaning":{"publicId":"3436899","version":"1","preferredName":"Stage IC Ovarian Cancer","longName":"3436899","preferredDefinition":"Stage IC includes: T1c, N0, M0. T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IC Ovarian Cancer AJCC v6 and v7","conceptCode":"C5222","definition":"Stage IC includes: T1c, N0, M0. T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-8134-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD822090-814D-307C-E040-BB89AD433070","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"ONEDATA","dateModified":"2012-04-12","deletedIndicator":"No"},{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE099F5F-BBAE-D133-E040-BB89AD434651","beginDate":"2012-04-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-19","modifiedBy":"ONEDATA","dateModified":"2012-04-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3436895","version":"1","preferredName":"Ovarian Cancer and Primary Peritoneal Carcinoma TNM Finding v7 American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system.  Ovarian cancer and primary peritoneal carcinoma are surgically/pathologically staged malignancies. (from AJCC 7th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C89637:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Cancer and Primary Peritoneal Carcinoma TNM Finding v7","conceptCode":"C89637","definition":"A finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system.  Ovarian cancer and primary peritoneal carcinoma are surgically/pathologically staged malignancies. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-80BA-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"ONEDATA","dateModified":"2012-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-80CB-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-12","modifiedBy":"COOPERM","dateModified":"2012-05-07","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3434441","version":"1","longName":"Ovarian","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"10000167","version":"1","longName":"Ovarian","context":"NCI Standards"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000689","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"BD926170-799D-C98B-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2012-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-13","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}